St. Jude Medical (STJ) Stock Down Despite Positive Earnings Report

NEW YORK (TheStreet) -- St. Jude Medical Inc (STJ) shares are down 2.9% to $61.36 in trading on Wednesday.

The stock dropped despite the cardiovascular medical device manufacturer increasing year over year revenue and beating analysts consensus estimates.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

St Jude Medical posted an EPS of 96 cents, beating Captial IQ first quarter estimate of 95 cents per share. Year to year quarterly revenue was up 2% to 1.36 billion, matching analysts estimates.

St. Jude also issued in line guidance ranges of 99 cents to $1.01 EPS for the second quarter and between $3.95 and $4 for the year.

TheStreet Ratings team rates ST JUDE MEDICAL INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate ST JUDE MEDICAL INC (STJ) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical